Form 4: Annovis Bio Director McCarthy Granted Stock Options
SEC Form 4
Director Reid McCarthy receives stock options in Annovis Bio, Inc.
Summary
- On November 17, 2023, Reid McCarthy, a director of Annovis Bio, Inc., was granted stock options to purchase 29,600 shares of common stock at an exercise price of $6.07.
- The options vest immediately and expire on November 17, 2033.
- The grant was made under the company's 2019 Equity Incentive Plan, which was amended on June 12, 2024, to increase the number of issuable shares from 2,000,000 to 3,000,000.
- 50% of the stock option grant was contingent upon the approval of the amendment.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard stock option grant, which is neither particularly positive nor negative on its own.
Positives
- The immediate vesting of the stock options could incentivize the director to work towards the company's success.
Industry Context
Stock option grants are a common practice to align the interests of company directors with those of shareholders, particularly in biotech companies like Annovis Bio.
Stakeholder Impact
- The stock option grant could potentially dilute existing shareholders if the options are exercised.
Key Dates
| Date | Description |
|---|---|
| 11/17/2023 | Date of the stock option grant to Reid McCarthy. |
| 06/12/2024 | Date of stockholder approval of the amendment to the 2019 Equity Incentive Plan. |
| 07/03/2024 | Date of the Form 4 filing. |
| 11/17/2033 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.